|
Sign In to gain access to subscriptions and/or personal tools.
|
This version was published on September
1, 2006
Journal of Biomolecular Screening, Vol. 11, No. 6,
575-585 (2006)
DOI: 10.1177/1087057106288051
Apoptotic Responses in Squamous Carcinoma and Epithelial Cells to Small-Molecule Toll-like Receptor Agonists Evaluated with Automated Cytometry
Jon R. Inglefield
Department of Pharmacology
Christopher J. Larson
Department of Pharmacology
Sheila J. Gibson
Department of Pharmacology
Hervé Lebrec
Department of Pathology-Toxicology, 3M Inc, Pharmaceuticals Division, St. Paul, Minnesota
Richard L. Miller
Department of Pharmacology
The authors describe an assay to quantitate DNA fragmentation using terminal deoxynucleotidyl transferase-mediated deoxyuri-dine triphosphate nick end-labeling (TUNEL) stain, adapted to a 96-well microplate format for adherent cells, and an automated high-content screening imager. The apoptotic responses to actinomycin D (a known antineoplastic agent) to imiquimod (a small-molecule toll-like receptor [TLR] 7 agonist used in skin cancer treatment) and to several structurally related TLR 7/8 agonists were evaluated in squamous carcinoma SCC15 and SCC25 cells and normal human keratinocytes. Potent proapoptotic and growth-impairing (as determined by reduced cell numbers) actions of actinomycin D (1-300 ng/mL) were discerned with the assay. Consistent with previous reports, imiquimod (at 300 µM; 75 µg/mL) induced TUNEL positivity of malignant cell cultures, but this effect also occurred in normal keratinocytes. Two related TLR agonists induced apoptosis at lower concentrations. However, the concentrations of these and the imiquimod necessary to elicit cancer cell apoptosis were 300 to 1000 times higher relative to their ability to induce the secretion of an antineoplastic protein, interferon- , from human blood monocytes. This TUNEL analysis allows the quantitative comparison of compounds apoptotic activity toward adherent malignant and normal cells and may be useful for hit characterization after a screen.
Key Words: apoptosis TUNEL method imidazoquinoline interferon cell-based assay cytomics Cellomics ArrayScan imiquimod
References
- Smolewski P, Bedner E, Du L, Hsieh TC, Wu JM, Phelps DJ, et al: Detection of caspases activation by fluorochrome-labeled inhibitors: multiparameter analysis by laser scanning cytometry. Cytometry 2001;44: 73-82.[CrossRef][ISI][Medline]
[Order article via Infotrieve]
- Lovborg H, Nygren P, Larsson R: Multiparametric evaluation of apoptosis: effects of standard cytotoxic agents and the cyanoguanidine CHS 828. Mol Cancer Ther 2004;3: 521-526.[Abstract/Free Full Text]
- Mooney LM, Al-Sakkaf KA, Brown BL, Dobson PR: Apoptotic mechanisms in T47D and MCF-7 human breast cancer cells. Br J Cancer 2002;87: 909-917.[CrossRef][ISI][Medline]
[Order article via Infotrieve]
- Crowe DL, Yoon E: A common pathway for chemotherapy-induced apoptosis in human squamous cell carcinoma lines distinct from that of receptor-mediated cell death. Anticancer Res 2003;23: 2321-2328.[ISI][Medline]
[Order article via Infotrieve]
- Cummings BS, Kinsey GR, Bolchoz LJ, Schnellmann RG: Identification of caspase-independent apoptosis in epithelial and cancer cells. J Pharmacol Exp Ther 2004;310: 126-134.[Abstract/Free Full Text]
- Saumet A, Slimane MB, Lanotte M, Lawler J, Dubernard V: Type 3 repeat/C-terminal domain of thrombospondin-1 triggers caspase-independent cell death through CD47/alphavbeta3 in promyelocytic leukemia NB4 cells. Blood 2005;106: 658-667.[Abstract/Free Full Text]
- Wright SC, Zhong J, Larrick JW: Inhibition of apoptosis as a mechanism of tumor promotion. FASEB J 1994;8: 654-660.[Abstract]
- Nickoloff BJ, Qin JZ, Chaturvedi V, Bacon P, Panella J, Denning MF: Life and death signaling pathways contributing to skin cancer. J Investig Dermatol Symp Proc 2002;7: 27-35.[CrossRef][ISI][Medline]
[Order article via Infotrieve]
- Bowen AR, Hanks AN, Allen SM, Alexander A, Diedrich MJ, Grossman D: Apoptosis regulators and responses in human melanocytic and keratinocytic cells. J Invest Dermatol 2003;120: 48-55.[CrossRef][ISI][Medline]
[Order article via Infotrieve]
- Chang AA, Van Waes C: Nuclear factor-KappaB as a common target and activator of oncogenes in head and neck squamous cell carcinoma. Adv Otorhinolaryngol 2005;62: 92-102.[Medline]
[Order article via Infotrieve]
- Ivanov VN, Bhoumik A, Ronai Z: Death receptors and melanoma resistance to apoptosis. Oncogene 2003;22: 3152-3161.[CrossRef][ISI][Medline]
[Order article via Infotrieve]
- Robinson J: Cytometry CD 8, 2004 [Online]. Retrieved from http://www.cytomics.info/index2.php?option=content&task=view&id=9&pop=1&page=0
- Bhawe KM, Blake RA, Clary DO, Flanagan PM: An automated image capture and quantitation approach to identify proteins affecting tumor cell proliferation. J Biomol Screen 2004;9: 216-222.[Abstract]
- Lovborg H, Gullbo J, Larsson R: Screening for apoptosis-classical and emerging techniques. Anticancer Drugs 2005;16: 593-599.[CrossRef][Medline]
[Order article via Infotrieve]
- Giuliano KA, DeBiasio RL, Dunlay RT, Gough A, Volosky JM, Zock J, et al: High-content screening: a new approach to easing key bottlenecks in the drug discovery process. J Biomol Screen 1997;2: 249-259.[Abstract]
- Dummer R, Urosevic M, Kempf W, Hoek K, Hafner J, Burg G: Imiquimod in basal cell carcinoma: how does it work? Br J Dermatol 2003;149(Suppl 66): 57-58.
- Urosevic M, Maier T, Benninghoff B, Slade H, Burg G, Dummer R: Mechanisms underlying imiquimod-induced regression of basal cell carcinoma in vivo. Arch Dermatol 2003;139: 1325-1332.[Abstract/Free Full Text]
- Hengge UR, Ruzicka T: Topical immunomodulation in dermatology: potential of toll-like receptor agonists. Dermatol Surg 2004;30: 1101-1112.[CrossRef][ISI][Medline]
[Order article via Infotrieve]
- Schon M, Bong AB, Drewniok C, Herz J, Geilen CC, Reifenberger J, et al: Tumor-selective induction of apoptosis by the small-molecule immune response modifier imiquimod. J Natl Cancer Inst 2003;95: 1138-1149.[Abstract/Free Full Text]
- Meyer T, Nindl I, Schmook T, Ulrich C, Sterry W, Stockfleth E: Induction of apoptosis by toll-like receptor-7 agonist in tissue cultures. Br J Dermatol 2003;149(Suppl 66): 9-14.
- Schon MP, Wienrich BG, Drewniok C, Bong AB, Eberle J, Geilen CC, et al: Death receptor-independent apoptosis in malignant melanoma induced by the small-molecule immune response modifier imiquimod. J Invest Dermatol 2004;122: 1266-1276.[CrossRef][ISI][Medline]
[Order article via Infotrieve]
- Testerman TL, Gerster JF, Imbertson LM, Reiter MJ, Miller RL, Gibson SJ, et al: Cytokine induction by the immunomodulators imiquimod and S-27609. J Leukoc Biol 1995;58: 365-372.[Abstract]
- Gorden KB, Gorski KS, Gibson SJ, Kedl RM, Kieper WC, Qiu X, et al: Synthetic TLR agonists reveal functional differences between human TLR7 and TLR8. J Immunol 2005;174: 1259-1268.[Abstract/Free Full Text]
- Giandomenico V, Vaccari G, Fiorucci G, Percario Z, Vannuchi S, Matarrese P, et al: Apoptosis and growth inhibition of squamous carcinoma cells treated with interferon-alpha, IFN-beta and retinoic acid are associated with induction of the cyclin-dependent kinase inhibitor p21. Eur Cytokine Netw 1998;9: 619-631.[ISI][Medline]
[Order article via Infotrieve]
- Shin DM, Glisson BS, Khuri FR, Clifford JL, Clayman G, Benner SE, et al: Phase II and biologic study of interferon alfa, retinoic acid, and cisplatin in advanced squamous skin cancer. J Clin Oncol 2002;20: 364-370.[Abstract/Free Full Text]
- Urosevic M, Dummer R, Conrad C, Beyeler M, Laine E, Burg G, et al: Disease-independent skin recruitment and activation of plasmacytoid predendritic cells following imiquimod treatment. J Natl Cancer Inst 2005;97: 1143-1153.[Abstract/Free Full Text]
- Kelly KJ, Sandoval RM, Dunn KW, Molitoris BA, Dagher PC: A novel method to determine specificity and sensitivity of the TUNEL reaction in the quantitation of apoptosis. Am J Physiol Cell Physiol 2003;284: C1309-C1318.[Abstract/Free Full Text]
- Mueller H, Kassack MU, Wiese M: Comparison of the usefulness of the MTT, ATP, and calcein assays to predict the potency of cytotoxic agents in various human cancer cell lines. J Biomol Screen 2004;9: 506-515.[Abstract]
- Andersson M, Sjostrand J, Petersen A, Honarvar AK, Karlsson JO: Caspase and proteasome activity during staurosporin-induced apoptosis in lens epithelial cells. Invest Ophthalmol Vis Sci 2000;41: 2623-2632.[Abstract/Free Full Text]
- Inglefield JR, Mundy WR, Shafer TJ: Inositol 1,4,5-triphosphate receptor-sensitive Ca(2+) release, store-operated Ca(2+) entry, and cAMP responsive element binding protein phosphorylation in developing cortical cells following exposure to polychlorinated biphenyls. J Pharmacol Exp Ther 2001;297: 762-773.[Abstract/Free Full Text]
- Kleeff J, Kornmann M, Sawhney H, Korc M: Actinomycin D induces apoptosis and inhibits growth of pancreatic cancer cells. Int J Cancer 2000;86: 399-407.[CrossRef][ISI][Medline]
[Order article via Infotrieve]
- Hines MD, Allen-Hoffman BL: Analysis of DNA fragmentation in epidermal keratinocytes using the apoptosis detection system, fluorescein. Promega Notes 1996;59: 30-33.
- Whiteside G, Cougnon N, Hunt SP, Munglani R: An improved method for detection of apoptosis in tissue sections and cell culture, using the TUNEL technique combined with Hoechst stain. Brain Res Brain Res Protoc 1998;2: 160-164.[CrossRef][Medline]
[Order article via Infotrieve]
- Ochs RL, Burholt D, Kornblith P: The ChemoFx assay: an ex vivo cell culture assay for predicting anticancer drug responses. Methods Mol Med 2005;110: 155-172.[Medline]
[Order article via Infotrieve]
- Nagourney RA, Brewer CA, Radecki S, Kidder WA, Sommers BL, Evans SS, et al: Phase II trial of gemcitabine plus cisplatin repeating doublet therapy in previously treated, relapsed ovarian cancer patients. Gynecol Oncol 2003;88: 35-39.[CrossRef][ISI][Medline]
[Order article via Infotrieve]
- Miller RL, Gerster JF, Owens ML, Slade HB, Tomai MA: Imiquimod applied topically: a novel immune response modifier and new class of drug. Int J Immunopharmacol 1999;21: 1-14.[CrossRef][ISI][Medline]
[Order article via Infotrieve]
- Mempel M, Voelcker V, Kollisch G, Plank C, Rad R, Gerhard M, et al: Toll-like receptor expression in human keratinocytes: nuclear factor kappaB controlled gene activation by Staphylococcus aureus is toll-like receptor 2 but not toll-like receptor 4 or platelet activating factor receptor dependent. J Invest Dermatol 2003;121: 1389-1396.[CrossRef][ISI][Medline]
[Order article via Infotrieve]
- Palamara F, Meindl S, Holcmann M, Luhrs P, Stingl G, Sibilia M: Identification and characterization of pDC-like cells in normal mouse skin and melanomas treated with imiquimod. J Immunol 2004;173: 3051-3061.[Abstract/Free Full Text]
- Barnetson RS, Satchell A, Zhuang L, Slade HB, Halliday GM: Imiquimod induced regression of clinically diagnosed superficial basal cell carcinoma is associated with early infiltration by CD4 T cells and dendritic cells. Clin Exp Dermatol 2004;29: 639-643.[CrossRef][ISI][Medline]
[Order article via Infotrieve]
- Smith KJ, Hamza S, Skelton H: Topical imidazoquinoline therapy of cutaneous squamous cell carcinoma polarizes lymphoid and monocyte/macrophage populations to a Th1 and M1 cytokine pattern. Clin Exp Dermatol 2004;29: 505-512.[CrossRef][ISI][Medline]
[Order article via Infotrieve]
- Salasche SJ, Levine N, Morrison L: Cycle therapy of actinic keratoses of the face and scalp with 5% topical imiquimod cream: an open-label trial. J Am Acad Dermatol 2002;47: 571-577.[CrossRef][ISI][Medline]
[Order article via Infotrieve]

CiteULike Connotea Del.icio.us Digg Reddit Technorati What's this?
This article has been cited by other articles:

|
 |

|
 |
 
E. L. J. M. Smits, P. Ponsaerts, Z. N. Berneman, and V. F. I. Van Tendeloo
The Use of TLR7 and TLR8 Ligands for the Enhancement of Cancer Immunotherapy
Oncologist,
August 1, 2008;
13(8):
859 - 875.
[Abstract]
[Full Text]
[PDF]
|
 |
|
|